EuroBiotech: More Articles of Note


> A leading British fund selector has reportedly pulled close to £300 million ($400 million) from one of Neil Woodford’s investment vehicles. The fund selector, Jupiter Asset Management, followed Woodford from Invesco Perpetual to his own startup investment outfit. But, against a backdrop of setbacks for Woodford’s portfolio companies, is said to have reduced its exposure to his flagship fund. Financial Times article

> Azura Ophthalmics raised $16 million to advance its treatment for meibomian gland dysfunction deeper into the clinic. OrbiMed, TPG Biotech and Brandon Capital led the investment in the Israeli biotech. Release

> Abingworth invested in VirionHealth. The British biotech will use the £13 million ($17 million) series A round to advance drugs that prevent and treat viral infections by outcompeting replication of the pathogens. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> ObsEva set up a $60 million private placement. The Swiss biotech expects to tap existing investors including New Enterprise Associates and Sofinnova Ventures for the cash. ObsEva is offering stock at $8 a pop, well below the $15 price it went public at earlier this year. Release  

> Kiadis Pharma raised €18 million ($21 million). The European biotech will use the money to fund a phase 3 trial of its lead candidate, ATIR101. Statement

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.